Cefodizime in acute purulent exacerbations of chronic respiratory disease.

Clinical, microbiological and pharmacokinetic studies were carried out after 1 or 2 g intramuscular injections bd of cefodizime (HR 221), a new aminothiazolyl cephalosporin, in 41 patients hospitalized for acute purulent exacerbations of chronic respiratory disease. Treatment was for 10 days. Serum Cmax values of 54.8 and 84.7 mg/l were recorded approximately 2 hours after the injections, the corresponding sputum values averaging 1.01 and 2.58 mg/l. Penetration from blood to sputum was 2 to 3.6%. The elimination phase half-life in serum was approximately 4.5 h. Clinical, microbiological and pharmacokinetic studies were carried out after 1 or 2 g intramuscular injections bd of cefodizime (HR 221), a new aminothiazolyl cephalosporin, in 41 patients hospitalized for acute purulent exacerbations of chronic respirators disease. Treatment was for 10 days. Serum Cmax values of 54.8 and 84.7 mg/l were recorded approximately 2 hours after the injections, the corresponding sputum values averaging 1.01 and 2.58 mg/l. Penetration from blood to sputum was 2 to 3.6%. The elimination phase half-life in serum was approximately 4.5 h.